HC Wainwright Trims KalVista Pharmaceuticals (NASDAQ:KALV) Target Price to $20.00

KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) had its price objective reduced by HC Wainwright from $24.00 to $20.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. Separately, Needham & Company LLC reiterated a buy rating and set a $35.00 price […]

Related Keywords

United States ,China ,New York ,Benjaminl Palleiko , ,Kalvista Pharmaceuticals Company Profile ,Kalvista Pharmaceuticals Price Performance ,China Universal Asset Management Co ,Tower Research Capital ,Kalvista Pharmaceuticals ,York State Common Retirement Fund ,News Ratings For Kalvista Pharmaceuticals Daily ,Hedge Funds Weigh In On Kalvista Pharmaceuticals ,Needham Company ,Securities Exchange Commission ,Kalvista Pharmaceuticals Inc ,Free Report ,Vista Pharmaceuticals ,Get Free Report ,Venrock Healthcare Capital Par ,Exchange Commission ,Research Capital ,Universal Asset Management ,New York State Common Retirement Fund ,Kalvista Pharmaceuticals Daily ,Nasdaq Kalv ,Kalv ,Medical ,Lower Price Target ,Hc Wainwright ,